
Alzheimer’s drug Leqembi gets full OK; Biotech’s H1 by the numbers; Bringing Leerink back; Against AI overhype; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Longtime readers would be familiar with our annual special report honoring women in biopharma R&D. This year we’ve moved the publication of the profiles and the accompanying event to July. We would love to see you there — you can find more details here.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.